

Title: The Bacteriophage Lambda CII Phenotypes for Complementation, Cellular Toxicity, and Replication Inhibition Are Suppressed in *cII-oop* Constructs Expressing the Small RNA OOP.

Author List and Affiliations: Karthic Rajamanickam and Sidney Hayes, Department of Microbiology and Immunology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5 Canada
 Corresponding author: sidney.hayes@usask.ca

Back Matter – Supplementary Materials

Figure S1. Sequence variations (1-3) of plasmid [cII₁₋₉₇] = [cII].


Figure S2. Deletions in *cII* and host mutations influencing CII complementation *in trans*.

Figure S3. Influence of *pO* variations on CII complementation *in trans*.


Table S1. Gene expression units cloned within plasmid vector pCIPR-[]-timm.

Table S2. Oligonucleotides used for plasmid construction and sequencing.


Plasmids 1: cII = cII₁₋₉₇, cII₁₋₈₇, cII₁₋₇₇, cII₁₋₆₇, cII₁₋₅₇, cII₁₋₄₇, cII-3638, cII-3639-3638+3639



Plasmids 2: cII-oop-pO94, cII-oop-pO45, cII-oop-pO-38383LK, cII-oop-pO45-38683-87MH



Plasmids 3: cII-cy3048, cII-cy2001, cII-cy42, cII-cy3001, sR-38339pE-cII, sR-38339pE-cII-oop-pO94



1 **Figure S1.** Sequence variations (1-3) of pClpR-cII-timm enabling *cII* expression arrangements. The point
2 mutations incorporated within *cII* or promoter *pO* were described in [1-4]. The sequences in *magenta*
3 are RBS. For the plasmids in sequences 1 & 2 the RBS is identical to 8 bases of the RBS consensus
4 sequence for gene *cro*. Sequences in *red* are “-10” promoter regions (for *pO*, in plasmid sequence 2; for
5 *pE*, in plasmid sequence 3). The sequences in *blue* (underlined) are for “-35” region of *pO* promoter
6 (sequence 2) and the suggested -35 region for the *pE* promoter (in sequence 3) within the N-terminal
7 sequence of *cII*. The sequence in *green* (shown sequence 2) represents the *oop* sequence encoding OOP
8 RNA. The Plasmids 1 include: *cII*, *cII*₁₋₉₂ (deleting five amino acids from the carboxy-terminal end of *cII*),
9 *cII*₁₋₈₇, *cII*₁₋₇₇, *cII*₁₋₆₇, *cII*₁₋₅₇, *cII*₁₋₄₇, *cII*-3638, *cII*-3639, *cII*-3638+3639. The sequence for Plasmids 2 include
10 the sequence 1 for WT *cII* plus the *oop* sequence that overlaps the carboxyl end of *cII*, plus the *pO*
11 sequence that overlaps with the sequence of N-terminal end of gene *O*: *cII*-*oop*-*pO*94, *cII*-*oop*-*pO*45, *cII*-
12 *oop*-*pO*45-38383LK, *cII*-*oop*-*pO*-38683-87MH. The sequence for Plasmids 3 include the WT *pE* promoter
13 from sR-38339-*pE*-*cII*, sR-38339*pE*-*cII*-*oop*-*pO*94 and *pE* mutations *cII*-*cy*3048, *cII*-*cy*2001, *cII*-*cy*42, and *cII*-
14 *cy*3001.

15

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

Plasmid in host cells	<i>λimm434cII2002</i> pfu spotted per overlay plate incubated at								
	30°C			37°C			39°C		
	~16,000	~160	~16	~16,000	~160	~16	~16,000	~160	~16
594 [<i>cII</i>]									
594 [<i>cII</i> ₁₋₉₂]									
594 [<i>cII</i> ₁₋₈₇]									
594 [<i>cII</i> ₁₋₇₇]									
594 <i>hflA::kan</i> [<i>cII</i>]									
594 <i>pcnB::kan</i> [<i>cII</i>]									
594 <i>rpoB</i> B8 [<i>cII</i>]									
594 <i>rpoB</i> D2 [<i>cII</i>]									
594 <i>rpoB</i> D2 [<i>cII</i> ₁₋₈₇]									

Figure S2. Deletions in *cII*, or host mutations influencing CII complementation *in trans*. Complementation of the *cII*-defect on the phage by the *cII* allele expressed from the plasmid was assessed by the ability of the spotted phage to form clear, turbid, or no pfu at 37 and 39°C. High expression of the Cl_{434} repressor made from the phage will fully repress its *oL* (not assayed) and *oR* transcription, preventing phage growth (pfu formation). An intermediate level of *cII* expression from the plasmid at 37°C can permit the otherwise clear plaque forming *λimm434 cII68* and *λimm434cII2002* phages (seen at 30°C) to form turbid plaques at 37°C. In contrast, the expression of the *cII* allele on the plasmid is blocked when the Ts Cl_{857} repressor is active in cells grown at 30°C.

1

Plasmid in host cells	<i>λimm434cII2002</i> pfu spotted per overlay plate incubated at								
	30°C			37°C			39°C		
	~16,000	~160	~16	~16,000	~160	~16	~16,000	~160	~16
594 [cII- <i>oop</i> -pO94] (p680)									
594 [cII- <i>oop</i> -pO94-38684-88MH] (p681)									
594 [sR38339-pE-cII] (p747)									
594 [sR38339-pE-cII- <i>oop</i> -pO94] (p748)									
594 [cII- <i>oop</i> -pO45WT] (p763)									
594 [cII- <i>oop</i> -pO45-38684-88MH] (p759)									
594 [cII- <i>oop</i> -pO45-38683LK] (p762)									

2

3

Figure S3. Influence of *pO* variations on CII complementation *in trans*.

4

5

6

7

8

9

10

11

12

13

14

15

1 **Supplemental tables**

2 **Table S1.** Gene expression units cloned within plasmid vector pcIpR-[]-timm.

3	Plasmid	Strain	Construction primer/ method employed
4	cII	p679	L-Bam-cII and R-ClaBsi-cII copy from p27R
5	cII-oop-pO94	p680	L-Bam-cII and R-Bsi-O-Po copy from p27R
6	cII-oop-pO94-38683-87MH	p681	L-Bam-cII and R-Bsi-O-Po copy from p27RpO
7	cII ₁₋₉₂	p696	L-Bam-cII and R-Cla-Bsi-CIIΔ15
8	cII ₁₋₈₇	p732	L-Bam-cII and R-Cla-Bsi-CIIΔ30
9	cII ₁₋₇₇	p715	L-Bam-cII and R-Cla-Bsi-CIIΔ60
10	cII ₁₋₆₇	p721	L-Bam-cII and R-Cla-Bsi-CIIΔ90
11	cII ₁₋₅₇	p723	L-Bam-cII and R-Cla-Bsi-CIIΔ120
12	cII ₁₋₄₇	p724	L-Bam-cII and R-Cla-Bsi-CIIΔ150
13	cII-oop-pO45WT	p763	L-Bam-cII and R-Bsi45poWT
14	cII-oop-pO45-38383LK	p762	L-Bam-cII and R-Bsi45po38383LK
15	cII-oop-pO45-38683-87MH	p759	L-Bam-cII and R-Bsi45po38684-88MH
16	cII-3638	p756	L-Bam-cII and R-Bsi-cII-3638
17	cII-3639	p757	L-Bam-cII and R-Bsi-cII-3639
18	cII-3638+3639	p758	L-Bam-cII and R-Bsi-3638+3639
19	sR-38339-cII-cy3048	p756	LXbaI-38339-cy3048 and R-ClaBsi-cII
20	sR-38339-cII-cy2001	p765	LXbaI-38339-cy2001 and R-ClaBsi-cII
21	sR-38339-cII-cy42	p764	LXbaI-38339-cy42 and R-ClaBsi-cII
22	sR-38339-cII-cy3001	p766	LXbaI-38339-cy3001 and R-ClaBsi-cII
23	sR-38339-pE-CII	p747	LBamXba38339 and R-nopo-Bsi-Cla (with WT cII stop)
24	sR-38339-pE-cII-oop-pO94	p748	LBamXba38339 and R-Bsi-O-po (with WT cII stop)
25			

26 **Table S2.** Oligonucleotides used for plasmid construction and sequencing.

Primer Name	5' to 3' Sequence
L37904+18	gctgctctgtgtaaatgg
R-153-19	gaagacagtcataagtgcgg
L-Bam-CII	atatggatccatggttctgtgcaaacacgaggctctacg
R-ClaBsi-CII	atatatcgatcgtagttagaactccatctggattgttcagaacgctcgg
R-Bsi-45poWT	atat cgtacgttactgccgaagttgagtattttgctgtattgtcataatgactcctgt
R-Bsi-45po38383LK	atatcgtacgttactgccgaagttgagtattttgctgtattgtcataaAgactcctgt
R-Bsi-45po38684-88MH	atatcgtacgttactgccgaagttgagtattttgctgtattgtcGCGGgactcctgt
R-Cla-Bsi-CII	atatatcgatcgtagttagaactccatctggattgttcagaacgctcgg
R-Cla-Bsi-CIIΔ15	atatatcgatcgtagttattgttcagaacgctcgggtgccgggctttttt
R-Cla-Bsi-CIIΔ30	atatatcgatcgtagttaggttgcggcgggcttttttattggtgagaatcgc
R-Cla-Bsi-CIIΔ60	atatatcgatcgtagttaaactgcagcaactgtcgcgccaatcgagccatgtc
R-Cla-Bsi-CIIΔ90	atatatcgatcgtagttacatgtc gtcgtcaacgacccccattcaagaacagc
R-Cla-Bsi-CIIΔ120	atatatcgatcgtagttaaagcaagcagcattgagaacttggatccagtc
R-Cla-Bsi-CIIΔ150	atatatcgatcgtagttaccagtcctctccactgctgatctgcgacttatc

L-BamXba38339new	atatggatcctctatctagatatctaaggaataacttacataggttcgtgc
R-noPo-Bsi-Clal	atatatcgatcgtagctcagaactccatctggattgttcagaacgctcgg
R-Bsi-O-Po	atatcgtacgtaacccatcatcgagatctgccacattacgctcctgtccggc
R-Bsi-CII-3638	atatcgtacgtagaactccaCctggattgttcagaacgctcgg
R-Bsi-CII-3639	atatcgtacgtagaactccat ctggattCgttcagaacgctcgg
R-Bsi-3638+3639	atatcgtacgtagaactccaCctggattCgttcagaacgctcgg
LXbal-38339-cy3048	atattctagatatcttaggaaGtacttacataggttcg
LXbal-38339-cy2001	atattctagatatcttaggaaatacGtacctacataggttcgtgc
LXbal-38339-cy42	atattctagatatcttaggaaatacttacataggttcgtgcTaacaaacgcaacgaggc
LXbal-38339-cy3001	atattctagatatcttaggaaatacttacataggttcgtgcaacaaacgTaacgaggctctacgaatc
L-Bam-OOP#1	atatggatcctggctcgattggcgcgacaagt
L-Bam-OOP#2	atatggatccgttgacgacgacatggctcgat
R-Cal-O	atatatcgattatagatccaccccgtaaattccagtc
R-Clal-36P	atatatcgattacctgctgtacctgctggcttttcgtcg
R-Clal-63P	atatatcgattacttcgttctggtcacggtagcc

1

2 **References**

- 3 1. Daniels, D. L., Schroeder, J.L., Szybalski, W., Sanger, F., and Blattner, F.R, Appendix I. A molecular map of
4 coliphage lambda. In *Lambda II*, R.W. Hendrix, J. W. R., F.S. Stahl, R.A. Weisberg, Ed. Cold Spring Harbor
5 Laboratory: Cold Spring Harbor, New York, 1983; pp 469-517.
6 2. Hayes, S.; Horbay, M. A.; Hayes, C., A CI-Independent Form of Replicative Inhibition: Turn Off of Early
7 Replication of Bacteriophage Lambda. *PLoS One* **2012**, 7, (5), e36498.
8 3. Krinke, L.; Mahoney, M.; Wulff, D. L., The role of the OOP antisense RNA in coliphage lambda
9 development. *Mol Microbiol* **1991**, 5, (5), 1265-72.
10 4. Wulff, D. L., Rosenberg, M.R., Establishment of repressor synthesis. In *Lambda II*, Hendrix, R. W.,
11 Roberts, J.W., Stahl, F.W., and Weisberg, R.A., Ed. Cold Spring Harbor Laboratory Press: Cold Spring
12 Harbor, NY, 1983; pp 519-684.

13